Lumida
/COO
⌘K
Cooper Companies Inc

Cooper Companies Inc

COO
$53.91USD↓-0.48%-0.26 today

MARKET CAP

10.3B

P/E (TTM)

26.8x

FWD P/E

—

DAY RANGE

$53 – $56

52W RANGE

$51
$90

AI Summary

Stalk
TrimMedium

COO has decisively broken key horizontal support and entered a Stage 4 decline with accelerating downside on heavy volume. Medium- and long-term structures are firmly bearish, and near-term indicators show an extended oversold condition. Execution favors trimming into weak rallies back toward the former support zone (near $67.98–$71.71), looking for rejection at declining EMAs and former support levels.

  • ↑EPS rose to $2.24 vs. $0.49 YoY, boosted by tax benefit.
  • ↑Free cash flow grew 66% to $273M, funding buybacks.
  • ↓Q4 EPS guidance of $1.05–$1.09 trails $1.20 consensus.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

The Cooper Companies Inc. (NYSE: COO) operates as a global medical device company specializing in contact lenses and surgical instruments. With its significant presence in the eye care space, CooperCompanies is a leading player through its two main business segments: CooperVision, focusing on soft contact lenses, and CooperSurgical, which specializes in fertility and gynecology products. The company is positioned well within the healthcare sector, benefiting from ongoing trends in vision care and reproductive health.

Bull says

  • ↑EPS rose to $2.24 vs. $0.49 YoY, boosted by tax benefit.
  • ↑Free cash flow grew 66% to $273M, funding buybacks.
  • ↑Buyback authorization increased to $3B, boosting shareholder returns.
  • ↑High institutional ownership reflects strong momentum and confidence.
  • ↑Defensive healthcare positioning offers stability in downturns.
  • ↑Valuation appears reasonable with high earnings yield and low volatility.

Bear says

  • ↓Q4 EPS guidance of $1.05–$1.09 trails $1.20 consensus.
  • ↓Revenue up just 1% YoY to $1.066B, below estimates.
  • ↓Negative growth and revisions factors signal weakening momentum.
  • ↓High sensitivity to rates and oil prices adds macro risk.
  • ↓Non-hormonal IUD competition may pressure CooperSurgical margins.
  • ↓Share price fell 6.2% after guidance, reflecting skepticism.

Investment themes with COO

Health Care Equipment & Supplies↑ +0.40%

Clinical instruments and devices powering patient care

ABT · ISRG · SYK
SPY↑ +0.09%

NVDA · AAPL · GOOGL
GS: Strong Pricing Power↑ +0.77%

Companies with strong ability to set prices

META · EA · PLTK

Earnings Call · Q3 2025 · Mgmt. Guidance

Updated 09-10-2026neutral

Transcript signals

Bull points

  • For the third fiscal quarter, consolidated revenues were $1.06 billion, up 5.7% as reported, and up 2% organically. Gross margin improved by 70 basis points to 67.3%, driven by continued efficiency gains, mix, and positive foreign exchange.
  • Operating income rose 8%, with operating margin expanding to 26.1%. Non-GAAP EPS was $1.10, up 15%.
  • Pre-cash flow was $165 million, with capex of $97 million. Net debt declined to $2.35 billion, and our bank-defined leverage ratio improved to 1.77 times.

Bear points

  • although it's too early to quantify any related charges or P&L benefits.
  • we saw greater than expected weakness within the pure play e-commerce segment in Asia-Pac, excluding Japan.
  • we're still seeing signs of pressure on the market, with clinics continuing to manage cash conservatively by delaying capital purchases and installations, along with ongoing softness and cycles in Asia-Pac.
Read full transcript analysis ›